Anzeige
Mehr »
Login
Samstag, 05.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Achtung Vervielfachung! URAN-AKTIEN starten durch …. Jetzt kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PXKZ | ISIN: CA77544C1041 | Ticker-Symbol: 8P2N
Frankfurt
04.10.24
08:04 Uhr
0,123 Euro
+0,003
+2,50 %
Branche
Öl/Gas
Aktienmarkt
Sonstige
1-Jahres-Chart
ROK RESOURCES INC Chart 1 Jahr
5-Tage-Chart
ROK RESOURCES INC 5-Tage-Chart
ACCESSWIRE
372 Leser
Artikel bewerten:
(2)

ROK Resources Inc.: ROK Resources Provides Second-Half 2024 Guidance

REGINA, SK / ACCESSWIRE / June 19, 2024 / ROK Resources Inc. ("ROK" or the "Company") (TSXV:ROK)(OTCQB:ROKRF) is pleased to outline its strategic direction for the second half of 2024, aimed at enhancing shareholder value through the development of conventional light oil prospects in core operating areas of Southeast Saskatchewan.

1H 2024 1

2H 2024

2024 Year

Capital Expenditures (MM)

$9.5

$14.5

$24.0

Daily Average Production (boepd) 2

4,000

4,300

4,150

Exit Production (boepd) 2,3

4,000

4,600

4,600

Funds from Operations (MM)

$15.0

$16.0

$31.0

Adjusted Net Debt (MM)

$16.5

$20.0

$20.0

Average WTI (US$)

$78/bbl

$75/bbl

$76.50/bbl

2024 Guidance Summary

Notes:

  1. Estimated prior to finalizing interim condensed financial statements for the six months ended June 30, 2024
  2. 64% liquids
  3. 1H 2024 exit production reduced by 280 boepd (80% natural gas) due to Kaybob, Alberta production shut-ins

2024 Guidance Highlights

  • Production Growth: Estimated 2024 average daily production rate of 4,100 boepd to 4,200 boepd (64% liquids) which exceeds 2023 daily average production rate of 3,876 boepd (62% liquids).
  • Reduction in Capital Expenditures: Total annual capital expenditures of $24 million to $25 million in 2024, a 25% decrease in annual capital expenditures when compared to 2023.
  • Stable Balance Sheet: 2024 exit Adjusted Net Debt of $19 million to $20 million, implying a debt to cash flow from operations ratio of 0.6x.
  • Core Area Drill Program: An estimated 13 gross (11.95 net) wells in Southeast Saskatchewan (75% - 85% Frobisher weighted assets), aimed at growing base reserves and future drilling inventory.
  • Midale Multi-Lateral Drilling: Drilling of 2 to 3 multi-lateral Midale wells to capitalize on Saskatchewan multi-lateral royalty incentive.
  • Strong Natural Gas Hedge Program: Total natural gas hedges of 1,094,563 MMBtu in 2H 2024 at an average price of $2.09/MMBtu, equating to an estimated hedge gain of $1.0 million to $1.5 million CAD at current strip pricing over this period.

Outlook

The Company is focused on using its current balance sheet to target strategic growth opportunities in core areas, while improving operational efficiencies through continued cost reduction measures. The drill program aims to add Frobisher drilling inventory in both new and existing areas, in addition to proving up Midale prospects with multi-lateral drilling.

Kaybob, Alberta Update

With the current softening of the North American natural gas markets, the Company has shut-in 280 boepd (80% natural gas) in its Kaybob, Alberta area. The strategic shut-ins are expected for the balance of Q3 2024 with reactivation expected in Q4 2024.

About ROK

ROK is primarily engaged in exploring for petroleum and natural gas development activities in Alberta and Saskatchewan. It has offices located in both Regina, Saskatchewan, Canada and Calgary, Alberta, Canada. ROK's common shares are traded on the TSX Venture Exchange under the trading symbol "ROK".

For further information, please contact:

Cameron Taylor, Chairman and Chief Executive Officer
Bryden Wright, President and Chief Operating Officer
Jared Lukomski, Senior Vice President, Land & Business Development
Lynn Chapman, Chief Financial Officer
Phone: (306) 522-0011
Email: investor@rokresources.ca
Website: www.rokresources.ca

Non-IFRS Measures

The non-IFRS measures referred to above do not have any standardized meaning prescribed by IFRS Accounting Standards ("IFRS") and, therefore, may not be comparable to similar measures used by other companies. Management uses this non-IFRS measurement to provide its shareholders and investors with a measurement of the Company's financial performance and are not intended to represent operating profits nor should they be viewed as an alternative to cash provided by operating activities, net income or other measures of financial performance calculated in accordance with IFRS. The reader is cautioned that these amounts may not be directly comparable to measures for other companies where similar terminology is used.

"Operating Income" is calculated by deducting royalties and operating expense from total sales revenue. Total sales revenue is comprised of oil and gas sales. The Company refers to Operating Income expressed per unit of production as an "Operating Netback". "Operating Income Profit Margin" is calculated by the Company as Operating Income as a percentage of oil and natural gas sales. "Funds from Operations" is calculated by adding other income and realized gains/losses on commodity contracts ("hedging") to Operating Income.

"Net Debt" includes all indebtedness of the Company, such as the Credit Facility and Lease Obligations (each as defined within the Company's interim condensed financial statements for the three months ended March 31, 2024), net of Adjusted Working Capital. "Adjusted Working Capital" is calculated as current assets less current liabilities, excluding current portion of debt and lease liability as defined on the Company's statement of financial position within the Company's interim condensed financial statements for the three months ended March 31, 2024. "Adjusted Net Debt" is calculated by removing the "mark-to-market fair value of the current portion of risk management contracts" and "lease obligations" (each as defined within the Company's interim condensed financial statements for the three months ended March 31, 2024) from Net Debt.

Conversion Measures

Production volumes and reserves are commonly expressed on a barrel of oil equivalent ("boe") basis whereby natural gas volumes are converted at the ratio of 6 thousand cubic feet ("Mcf") to 1 barrel of oil ("bbl"). Although the intention is to sum oil and natural gas measurement units into one basis for improved analysis of results and comparisons with other industry participants, boe's may be misleading, particularly if used in isolation. A boe conversion ratio of 6 Mcf to 1 bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. In recent years, the value ratio based on the price of crude oil as compared to natural gas has been significantly higher than the energy equivalency of 6:1 and utilizing a conversion of natural gas volumes on a 6:1 basis may be misleading as an indication of value.

Abbreviations

bbls/d barrels per day
bopd barrels per day
boepd barrels oil equivalent per day
IP Initial Production
NGLs Natural Gas Liquids
Mboe Thousands of barrels of oil equivalent
Mg/l Milligrams per Litre
MMboe Millions of barrels of oil equivalent
PDP Proved Developed Producing
TP Total Proved Reserves
TPP Total Proved and Probable Reserves
WTI West Texas Intermediate, the reference price paid in U.S. dollars at Cushing, Oklahoma for the crude oil standard grade
CA$ Canadian dollars
US$ U.S. dollars

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the Company's objectives, goals, or future plans and the expected results thereof. Forward-looking statements are necessarily based on several estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to general business, economic and social uncertainties; litigation, legislative, environmental, and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in ROK's public documents filed on SEDAR+ at www.sedarplus.ca; and other matters discussed in this news release. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether because of new information, future events, or otherwise.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility of the adequacy or accuracy of this release.

SOURCE: ROK Resources Inc.



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.